Related Experiment Video

Updated: Jan 15, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.8K

Lenalidomide-associated reversible TP53-mutated clonal hematopoiesis in plasma cell neoplasms

Christian B Gocke1, Mareike Peters2, Christopher D Gocke3

  • 1Department of Oncology, Johns Hopkins University School of Medicine. cgocke2@jhmi.edu.

Haematologica
|October 16, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.7K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

9.9K

Related Experiment Videos

Last Updated: Jan 15, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.8K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.7K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

9.9K

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

4.1K
Commitment is the  process whereby stem cells:
4.1K

Articles linked to this work by shared authors, journal, and citation graph.

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Blood·2026

SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes.

Clinical lymphoma, myeloma & leukemia·2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026

Long-Term Storage of Formalin-Fixed Paraffin-Embedded Tissues Negatively Impacts Next-Generation Sequencing: Successful Restoration with a DNA Repair Enzyme.

Clinical chemistry·2026

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Haematologica·2026

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Haematologica·2026

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Haematologica·2026

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Haematologica·2026

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Haematologica·2026

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Haematologica·2026

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Haematologica·2026

RUNX1 upregulation and RUNX1-ETO depletion inhibits survival of t(8;21)-positive leukemia cells.

Global medical genetics·2026

Peripheral immune dynamics during treatment predict prognosis in HCC receiving TACE plus ICIs and anti-VEGF/TKIs.

Clinical & translational immunology·2026

ALK regulates macrophage polarization via the USP7/SOX9/MFAP2-mediated glycolytic pathway to promote neuroblastoma progression.

Cellular signalling·2026

Epigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies.

Transplantation and cellular therapy·2026

GIANT CUTANEOUS HORN OF THE CHEEK: A CLINICAL CASE REPORT.

Georgian medical news·2026

Tetracycline-loaded nanomotors target neutrophil activation and oxidative stress in acute lung injury.

iScience·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us